Evidence map›Paper›PMID 40729735›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

A Prion-Like Domain in EBV EBNA1 Promotes Phase Separation and Enables SRRM1 Splicing.

Xiaoyue Zhang, Zhengshuo Li, Run Zheng, Xiang Zheng, Jia Wang, Can Liu, Yangge Wu, Yuqing Wen, Chunlin Ou, Songqing Fan and 8 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. A Prion-Like Domain in EBV EBNA1 Promotes Phase Separation and Enables SRRM1 Splicing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Xiaoyue ZhangHunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Zhengshuo LiHunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Run ZhengHunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Xiang ZhengDepartment of Pathology, The First Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, 541001, China.
Jia WangDepartment of Immunology, Changzhi Medical College, Changzhi, Shanxi, 046000, China.
Can LiuHunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Yangge WuHunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Yuqing WenHunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Chunlin OuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Songqing FanDepartment of Pathology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Chenxiao XuHunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Junrui TianHunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Qun YanDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, 410008, China.
Hao NanCollege of Life Sciences, Northwest A&F University, Yangling, Shaanxi, 712100, China.ORCID https://orcid.org/0000-0002-4028-5974
Xiaodong XuCollege of Life Sciences, Northwest A&F University, Yangling, Shaanxi, 712100, China.ORCID https://orcid.org/0000-0001-6452-8419
Hui WangHunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Qiu PengHunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Jian MaHunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.ORCID https://orcid.org/0000-0001-9395-0416

Funding

China 111 Project 111-2-12China Postdoctoral Science Foundation 2024M753677China Postdoctoral Science Foundation 2025M771479Department of Education of Hunan Province 23A0016National Natural Science Foundation of China 32000665National Natural Science Foundation of China 82060042National Natural Science Foundation of China 82203233National Natural Science Foundation of China 82373062National Natural Science Foundation of China 82472701Natural Science Foundation of Changsha kq2502216Postdoctoral Fellowship Program of CPSF GZC20242037Postdoctoral Science Foundation of Central South University 140050041Science and Technology Program of Hunan Province 2024JJ4025Science and Technology Program of Hunan Province 2024JJ6551Science and Technology Program of Hunan Province 2024RC3231Science and Technology Program of Hunan Province 2025JK2138
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) is necessary to maintain stability of EBV episomes, EBV replication, and causes host genomic instability and promotes tumor cells survival. Recent studies have shown that viruses utilize liquid-liquid phase separation (LLPS) within host cells to form sub-cellular compartments known as "virus factories". Prion-like domains (PrLDs), which resemble structural domains of low complexity, are shown to drive LLPS in vivo. In the current study, a PrLD is identified in EBNA1 and aggregation of EBNA1 proteins is observed in EBV-positive tumors. EBNA1 condensate interacting molecules are examined and are found that EBNA1 interacts with the splicing factor SRSF1 to regulate alternative splicing of SRRM1 and promote tumor progression. Deleting the EBNA1 PrLD results in defects in protein aggregation, LLPS, alternative splicing regulation, and nasopharyngeal carcinoma cells proliferation. Targeting the PrLD of EBNA1 inhibits the formation of protein aggregation, promotes alternative splicing of SRRM1, and inhibits the progression of nasopharyngeal carcinoma. Here, we report for the first time that EBNA1, a protein from the human oncogenic virus EBV, is a prion-like protein, combining algorithm prediction and experimental validation. That implies a possible molecular pathogenic mechanism of EBNA1 in neurodegenerative diseases.

Indexed as

Epstein-Barr Virus Nuclear AntigensHerpesvirus 4, HumanPrionsRNA-Binding ProteinsSerine-Arginine Splicing FactorsAlternative SplicingCell Line, TumorEpstein-Barr Virus InfectionsHumansPhase SeparationEBV-encoded nuclear antigen 1Epstein-Barr Virus Nuclear AntigensPrionsRNA-Binding ProteinsSerine-Arginine Splicing FactorsSRSF1 protein, humanalternative splicingEBV‐encoded nuclear antigen 1phase separationprion‐like domainprotein aggregation

Identifiers

PMID40729735
PMCPMC12591112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.